Table of Contents

company-logo

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Lineage Cell Therapeutics Dividend Announcement

• Lineage Cell Therapeutics announced a annually dividend of $0.08 per ordinary share which will be made payable on . Ex dividend date: 2003-12-15
• Lineage Cell Therapeutics's trailing twelve-month (TTM) dividend yield is -%

Lineage Cell Therapeutics Dividend History

Ex-Div dateDividend amountDividend typePay date
2003-12-15$0.08annually

Lineage Cell Therapeutics Dividend per year

Lineage Cell Therapeutics Dividend Yield

Lineage Cell Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Lineage Cell Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Lineage Cell Therapeutics Financial Ratios

P/E ratio-7.37
PEG ratio-0.27
P/B ratio2.61
ROE-35.54%
Payout ratio0.00%
Current ratio2.64
Quick ratio2.64
Cash Ratio1.94

Lineage Cell Therapeutics Dividend FAQ

Does Lineage Cell Therapeutics stock pay dividends?
Lineage Cell Therapeutics does not currently pay dividends to its shareholders.
Has Lineage Cell Therapeutics ever paid a dividend?
No, Lineage Cell Therapeutics has no a history of paying dividends to its shareholders. Lineage Cell Therapeutics is not known for its dividend payments.
Why doesn't Lineage Cell Therapeutics pay dividends?
There are several potential reasons why Lineage Cell Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Lineage Cell Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Lineage Cell Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Lineage Cell Therapeutics a dividend aristocrat?
Lineage Cell Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Lineage Cell Therapeutics a dividend king?
Lineage Cell Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Lineage Cell Therapeutics a dividend stock?
No, Lineage Cell Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Lineage Cell Therapeutics stocks?
To buy Lineage Cell Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Lineage Cell Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.